New fast insulin tested in chinese diabetes patients

NCT ID NCT04698018

Completed Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how quickly a fast-acting insulin (faster aspart) enters the blood in 23 Chinese adults with type 1 or type 2 diabetes. Participants received one injection of faster aspart and one of the standard insulin NovoRapid, in random order. Blood samples were taken over 12 hours to compare how the two insulins work.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 1 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 1 diabetes mellitus type 1 diabetes mellitus 1 type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES MELLITUS, TYPE 1 DIABETES MELLITUS, TYPE 2

Contacts and locations

Locations

Phase 1 Clinical Trial Centre

Shatin, New Territories, Hong Kong, Postal Code: NA, Hong Kong
Phase 1 Clinical Trial Centre

Shatin, New Territories, Hong Kong
Profil Institut für Stoffwechselforschung GmbH

Neuss, 41460, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.